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http://dx.doi.org/10.1016/j.jmii.2013Background: Kawasaki disease shock syndrome (KDSS) is a severe condition related to Kawasaki
disease (KD), and sometimes it is difficult to diagnose. This is a caseecontrol study to ascertain
the clinical presentations, risk factors, and clinical outcomes of children who had KDSS.
Materials and methods: Children who were hospitalized during 2001e2011 with the diagnosis of
KD combinedwith hypotension, sepsis, or shockwere retrospectively reviewed andwere defined
as case patients. For each case patient, three season-matched patients diagnosed as having KD
with normal blood pressure were identified to serve as control patients. Demographic character-
istics, clinical presentations, laboratory features, therapies, and outcomes were analyzed.
Results: Nine KDSS patients and 27 control patients were identified. The average age of patients
with KDSS was 3.2  3.2 years. Compared with controls, KDSS patients were less likely to have a
diagnosis of KD at admission (22.2% vs. 66.7%) and had a higher risk of coronary artery dilatation
(77.8% vs. 11.1%). Risk factors for KDSS included higher neutrophil counts and proportions of
bands, higher C-reactive protein (CRP), and lower platelet counts. All case patients received
aspirin therapy; eight patients received intravenous immunoglobulin therapy,with two receiving
more than one course. Seven KDSS patients required fluid resuscitation, and eight patients
required vasoactive infusions.
Conclusion: Patients with KDSS may have uneven clinical course and may bemisdiagnosed in the
beginning. They may have more prominent inflammatory markers in the early phase and higher
risk of coronary artery dilatation.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.of Pediatrics, Mackay Memorial Hospital, 92, Section 2, Chung-Shan North Road, Taipei, Taiwan.
rg.tw (N.-C. Chiu).
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Kawasaki disease (KD) is a generalized systemic vasculitis
predominantly involving medium-sized arteries, and the
etiology is still ill defined.1 The prevalence of KD is higher in
Asian countries than in western countries. Japan has the
highest annual incidence rate, followed by Korea and
Taiwan, and the lowest rate is seen in Europe.2e7 The se-
vere complication of KD is the occurrence of coronary ar-
tery lesions and this often occurs in the subacute phase.8
There is a 15e25% incidence of coronary artery lesions
developing in KD patients without early treatment.2 It is
also the leading cause of acquired heart disease in chil-
dren.9 If the aneurysm persists and becomes occlusive, it
may increase the risk of myocardial infarction or sudden
death.1,10
However, hemodynamic instability during the acute
phase of KD is uncommon. Kanegaye et al described the
phenomenon and defined the term as KD shock syndrome
(KDSS) in 2009.11 The exact cause of severe hypotension in
patients with KD is unknown. It is probably multifactorial,
possibly including vasculitis with ongoing capillary leakage,
myocardial dysfunction, and cytokine dysregulation.12
From January 2001 to December 2011 in our hospital, we
observed a number of children, admitted to the ICU, with a
presumptive diagnosis of hypotension, toxic shock, or sep-
tic shock, and/or requiring hemodynamic support, later
confirmed with a diagnosis of KD. They fulfilled the defini-
tion of KDSS. We performed this caseecontrol study,
comparing them with KD patients, to ascertain the clinical
presentations, risk factors, and clinical outcomes of chil-
dren who had KDSS.Materials and methods
Patient selection
Hospitalized patients, ranging in age from 1 month to 18
years, diagnosed as KD were selected from discharge re-
cords [acute febrile mucocutaneous lymph node syndrome,
International Classification of Diseases (ICD) Ninth Revision
codes 4461] during the period from January 2001 to
December 2011. Owing to the fact that the term KDSS has
just been recently defined, earlier cases presenting as
septic shock, toxic shock, or hypotension might have been
missed. We searched the patients who were discharged
from the intensive care unit (ICU) with diagnoses of KD
combined with hypotension (ICD codes 4589), shock (ICD
codes 78550), or sepsis (ICD codes 0389), and defined them
as case patients (KDSS patients). For each case patient, we
identified three season-matched patients who were diag-
nosed as KD with normal blood pressure, matched to each
case patient by date of admission 4 weeks, and defined
them as control patients (KD patients). All patients
receiving a diagnosis of KD were confirmed by our pediatric
infectious disease specialists during their hospitalization.
We retrospectively reviewed the medical records of these
children, including demographic characteristics, clinical
presentations, laboratory features, cardiac sonographic
findings, therapies, and outcomes.Definitions
Complete KD patients needed to present with fever for at
least 4 days and at least four principal features (poly-
morphous exanthema, bilateral bulbar conjunctival injec-
tion without exudate, cervical lymphadenopathy, changes
in lips and oral cavity, and changes in the extremities).
Incomplete KD patients had persistent fever but fewer than
four of the five characteristics and laboratory and/or
echocardiographic data could assist in the diagnosis. Day 1
of illness was defined as the first day of fever. Intravenous
immunoglobulin (IVIG) refractory disease was defined as
persistence or recrudescence of fever <48 hours after
completion of IVIG infusion (2 g/kg). Echocardiography was
performed during the acute (0e10 days after disease
onset), subacute (11e21 days), convalescent (22e90 days),
and chronic (91e365 days) phases. The definition of coro-
nary artery dilatation was according to the diagnostic
criteria and reporting of coronary artery lesions in Kawasaki
disease by the Japanese Ministry of Health and Welfare: if
the internal diameter of a segment measures 3 mm in
children aged <5 years or >4 mm in children aged >5 years;
if the internal diameter of a segment measures >1.5 times
that of an adjacent segment; or if the coronary lumen is
clearly irregular.13
Statistical analysis
We performed bivariate comparisons by using the Man-
neWhitney U test for medians and the Fisher’s exact test
for dichotomous or ordinal variables, as appropriate.
Multivariate logistic regression analysis was also used. A p
value <0.05 was considered statistically significant.Results
Demographic and clinical characteristics
During the 11-year period, nine patients were identified as
KDSS patients, and 27 season-matched subjects were
identified as control patients (KD patients). The de-
mographic and clinical characteristics of patients with KDSS
are shown in Table 1. Most KDSS patients did not receive the
diagnosis of KD on admission. Only one of these nine KDSS
patients was directly admitted to the ICU from the emer-
gency department due to gastrointestinal (GI) bleeding and
suspected septic shock, and the remaining eight patients
were admitted initially to the general wards and then
transferred to the ICU due to deteriorating conditions. The
patients with KDSS were more commonly females, with a
ratio of 2:1 over males. The average age was 3.2  3.3
years. The duration for diagnosis of Kawasaki disease was
3.3  3.3 days after admission. The most common clinical
features at time of presentation were conjunctivitis,
oralemucosal change, and skin rash. Two KDSS patients
presented with incomplete KD features. Case 2 had signs of
fissure lips and strawberry tongue, erythema and swelling
of palms and feet, skin rash, and coronary artery dilatation.
Case 5 had signs of conjunctivitis, fissure lips, skin rash, and
coronary artery dilatation.
























1 1.9 M 4 11 Generalized
lymphadenitis
GI bleeding, sepsis 11 X X X a
2 0.1 F 29 46 Fever Seizure, respiratory
distress
15 X X a, b, c





8 X X X a, b, c
4 3.9 F 7 18 Neck lymphadenitis Sepsis, hypotension 5 X X X a, c
5 7.0 F 7 9 Fever Septic shock 7 X X a
6 0.9 F 4 10 Acute
gastroenterocolitis,
Kawasaki disease
Sepsis, hypotension 8 X X X a
7 10.0 M 7 12 Neck lymphadenitis,
toxic
erythema
Sepsis, hypotension 10 X X X a
8 2.7 F 10 13 Retropharyngeal
abscess
Respiratory distress 11 X X X X
9 2.3 F 4 11 Fever Septic shock 6 X X X a




















Table 2 Comparison of demographic and clinical charac-
teristics between patients with Kawasaki disease shock






Female sex, no. (%) 6 (66.7) 11 (40.7) 0.26
Age (y) 3.2  3.3 2.0  1.8 0.31
Diagnosis time after
admission (d)
3.3  3.3 1.0  1.7 0.07
KD as initial diagnosis, no.
(%)
2 (22.2) 18 (66.7) 0.05
Febrile duration (d) 9.0  3.1 7.1  2.3 0.12
Highest body temperature
(C)
39.6  0.6 39.9  0.6 0.35
Body temperature >40 C,
no. (%)
23 (33.3) 11 (42.3) 0.71
Complete KD, no. (%) 7 (77.8) 17 (63.0) 0.69
Hospitalized duration (d) 15.8  11.6 6.6  2.2 0.05
46 P.-S. Chen et al.The comparisons of demographic characteristics and
clinical characteristics between the KDSS patients and the
KD patients are shown in Table 2. KDSS patients were less
likely to have an initial diagnosis of KD compared with
controls (22.2% vs. 66.7%, pZ 0.05). The median length of
hospital stay was 9.2 days longer for KDSS patients
compared with KD patients (p Z 0.05). There were no
significant differences in age, sex, febrile days, illness
duration, or percentage of complete KD between groups.Table 3 Comparison of laboratory data between patients with K
(KD)
KDSS (n Z 9)
WBC count (109/L) 14.5  7.0
WBC >15  109/L, no. (%) 3 (33.3)
WBC >17  109/L, no. (%) 3 (33.3)
Bands (%) 17.1  14.7
Bands >6%, no. (%) 6 (66.7)
Bands >10%, no. (%) 5 (55.6)
PMNs (%) 69.7  18.1
PMNs >75%, no. (%) 5 (55.6)
Platelet count (109/L) 171.1  97.8
Platelet <100  109/L, no. (%) 3 (33.3)
ESR (mm/h) 50.6  29.9
ESR >40 mm/h (%) 40.0
CRP (mg/dL) 21.3  13.4
CRP >10 mg/dL (%) 80.0
Albumin (g/dL) 2.2  0.3
Albumin <3 g/dL (%) 100.0
GOT (IU/L) 66.7  77.2
GOT >50 IU/L (%) 33.3
GPT (IU/L) 59.2  43.7
GPT >50 IU/L (%) 44.4
Pyuria (> 5 WBCs/HPF), % 33.3
Blood culture negative (%) 100.0
CRP Z C-reactive protein; ESR Z erythrocyte sedimentation rate; G
oyruvate transaminase; HPF Z high-power field; KD Z Kaw
PMNs Z polymorphonuclear neutrophils; WBC Z white blood cell.Laboratory data
The KDSS patients had significantly higher proportions of
bandemia (pZ 0.001), neutrophilia (pZ 0.03), thrombocy-
topenia (pZ 0.01), higher C-reactive protein (CRP) concen-
trations (pZ 0.02), andhypoalbuminemia (pZ 0.01) thanKD
patients (Table 3). There were no significant differences in
white blood cell counts, erythrocyte sedimentation rate,
glutamate oxaloacetate transaminase (GOT) level, gluta-
mate pyruvate transaminase (GPT) level, or percentage of
pyuria between both groups. Seven (77.8%) of the KDSS pa-
tients had hyponatremia (sodium<135mM), four (44.4%) had
metabolic acidosis (bicarbonate <18 mM), and two (22.2%)
had higher creatinine concentration (creatinine >1.0 mg/
dL). Four patients (44.4%) had low platelet counts (<
100 109/L), three (33.3%) with positive D-dimer results, and
five (55.5%) with prolonged prothrombin times/partial pro-
thrombin times for age. Three (33.3%) of the KDSS patients
and two (7.4%) of the KD patients performed a lumbar punc-
ture, but neither group showed evidence of CSF pleocytosis.
Echocardiographic findings
All KDSS patients underwent echocardiography during the
acute phase, seven patients during the subacute phase,
seven during the convalescent phase, and six during the
chronic phase. The KDSS patients had higher risk of coro-
nary artery abnormality compared with KD patients (77.8
vs. 11.1 %, p < 0.001; Table 4). Four (44.4%) patients had
persistent coronary artery dilatation until the convalescentawasaki disease shock syndrome (KDSS) and Kawasaki disease
KD (n Z 27) p
13.5  4.9 0.70
7 (25.9) 0.69
5 (18.5) 0.38
3.1  9.0 0.02
2 (7.4) 0.001
2 (7.4) 0.01
60.5  19. 5 0.22
4 (14.8) 0.03
361.0  126.8 <0.001
0 (0.0) 0.01
51.4  25.3 0.96
69.2 0.33
6.2  4.9 0.06
17.6 0.02
3.4  0.9 0.02
33.3 0.01
88.2  140.2 0.63
33.3 >0.99




OT Z glutamate oxaloacetate transaminase; GPT Z glutamate
asaki disease; KDSS Z Kawasaki disease shock syndrome;
Table 4 Comparison of cardiac sonographic findings between patients with Kawasaki disease shock syndrome (KDSS) and
Kawasaki disease (KD)
Echocardiographic findings KDSS (n Z 9)
no. (%)
KD (n Z 27)
no. (%)
p
Overall Coronary artery dilatation 7 (77.8) 3 (11.1) <0.001
Acute phase Coronary artery dilatation 5 (55.5) 2 (7.4) 0.01
RCA 4 (44.4) 1 (3.7) 0.01
LCA 4 (44.4) 1 (3.7) 0.01
Convalescent phase Coronary artery dilatation 4 (44.4) 0 (0.0) 0.002
Coronary artery dilatation 4 (55.5) 1 (3.7) 0.01
RCA ectasia 1 (11.1) 0 (0.0) 0.25
Chronic phase Coronary artery dilatation 2 (22.2) 0 (0.0) 0.06
MR/TR 2 (22.2) 0 (0.0) 0.06
LCA Z left coronary artery; MR Z mitral regurgitation; RCA Z right coronary artery; TR Z tricuspid regurgitation.
Kawasaki disease shock syndrome 47phase. Case 2 had mitral regurgitation during the subse-
quent period of 4.5 years, Case 4 had right coronary artery
ectasia after 3.5 months of illness, which then became
persistent right coronary artery dilatation during the sub-
sequent period of 6 years, and Case 7 had dilated right
ventricle, mitral regurgitation, and tricuspid regurgitation
during the subsequent period of 2 years and then recovered
to a normal state after 2.2 years.Clinical outcomes and management
All KDSS patients received aspirin therapy. Four KDSS pa-
tients used high dose aspirin initially, and the others started
with low dose aspirin because thrombocytopenia, GI hem-
orrhage, or fever had subsided when KD was diagnosed.
Eight KDSS patients received IVIG, and the time of first IVIG
therapy was 2.3  2.1 days after admission and 5.0  2.0
days after onset of symptoms. Two of the KDSS patients had
IVIG-refractory disease and required further IVIG treat-
ments, but there was no IVIG-refractory case in the KD
patients (p Z 0.06). Seven of the KDSS patients received
fluid resuscitation, eight required vasoactive agents, threeTable 5 Comparison of therapy between patients with







Duration from admission to
IVIG therapy (d)
2.3  2.1 1.4  1.1 0.22
Duration from symptom
onset to IVIG therapy (d)
5.0  2.0 4.8  1.5 0.75
Received aspirin, no. (%) 9 (100.0) 27 (100.0) >0.99
Received IVIG, no. (%) 8 (88.9) 20 (74.1) 0.65
Second dose of IVIG, no. (%) 2 (22.2) 0 (0.0) 0.06
Received antibiotics, no. (%) 9 (100.0) 17 (63.0) 0.04
Requiring vasoactive
infusions, no. (%)
8 (88.9) 0 (0.0) <0.001
Requiring albumin, no. (%) 9 (100.0) 0 (0.0) <0.001
IVIG Z intravenous immunoglobulin.required blood transfusion, and all nine patients received
albumin infusion (Table 5). The vasoactive agents, dobut-
amine, dopamine, and epinephrine, were prescribed indi-
vidually or in combination. The average duration of
vasoactive agent use was 6.0  4.5 days.
Multivariate logistic regression analysis for risk
factors
The KDSS patients had a greater chance of coronary artery
dilatation, might need more than one dose of IVIG therapy,
and had risk factors, i.e., bandemia, neutrophilia, throm-
bocytopenia, and elevated CRP (Table 6).
Discussion
The etiology of KD is still unclear and there is no single
pathognomonic clinical or laboratory finding for the diag-
nosis. We know that it is a systemic inflammatory reaction,
resulting in vasculitis and even coronary artery lesions.
Some researchers think that an infectious agent triggers an
inflammatory response, resulting in host immune dysregu-
lation in genetically predisposed individuals.14,15 Several
studies support the hypothesis through the study of the
genome-wide associated with KD in individuals of Japanese,
Korean, Taiwanese, and European descent.3,16e19
In our 11-year study period, there were nine patients
(1.9% of total KD patients) admitted to our ICU due to hy-
potension, shock, or sepsis. Kanegaye et al reported that 7%
of KD patients had shock syndrome, and 31% of KDSS pa-
tients had ejection fraction <54%.11 Dominguez et al found
that 3.3% of KD patients were admitted to the ICU during
the acute phase.12 The above cases presented with atypical
features, prominent inflammatory markers and severe
clinical conditions, so it was difficult to diagnose KD early.
Our prevalence of KDSS was lower than the above studies,
and numbers might be underdiagnosed because of their
atypical manifestations.
Recently, several studies have described case reports of
KD patients combined with initial presentations of shock
syndrome.20e24 The cause of severe hypotension in patients
with KD is unknown. Some authors propose the hypothesis
of proinflammatory cytokine overexpression in KD, which
Table 6 Multivariate logistic regression analysis for risk
factors of Kawasaki disease shock syndrome (KDSS)
Odds ratio p
Female sex 0.403 0.53
WBC >15  109/L 0.131 0.72
Band >6% 7.138 0.01
PMN >75% 4.738 0.03
Platelets <100  109/L 15.812 <0.001
CRP >10 mg/dL 6.431 0.01
Coronary artery dilatation 13.125 <0.001
BT >40 C 0.022 0.88
Second IVIG 7.047 0.02
BT Z body temperature; CRP Z C-reactive protein;
IVIGZ intravenous immunoglobulin; PMNZ polymorphonuclear
neutrophil; WBCZ white blood cells.
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ported one case of a KD patient with suspected develop-
ment of a systemic capillary leak syndrome (SCLS).25 SCLS is
reversible plasma extravasation and vascular collapse
accompanied by hypoalbuminemia due to increased
vascular leakage.25,26 These patients could experience
shock and noncardiogenic edema and be treated with
vasopressor therapy and colloid solutions for osmotic ef-
fects. SCLS could also occur in patients with KD because
elevated interleukin-2 increased endothelial permeability,
and IVIG might have a beneficial effect by post-
transcriptional interleukin-2 suppression.27 Two recent
studies suggest that KD patients with shock have more se-
vere systemic inflammation associated with myocardial
involvement.11,12
Myocardial destruction linked to acute myocarditis is
suggested by the elevated troponin I level in another
study.25 Kim et al found a significant elevation in the
troponin I level in the acute phase of KD. 28 However,
Checchia et al reported no significant increase in the
troponin I level in KD patients.29 In our study, the troponin I
level was only examined in four KDSS patients when they
were initially admitted to the ICU, and only one had an
elevated troponin I level.
A high proportion of KDSS patients in our study (7/9) had
coronary artery abnormalities, which was in keeping with
the reported increased risk of coronary artery abnormality
in KD with shock from other studies.11,12,21,30 Mitral
regurgitation and left ventricle dysfunction have been
widely discussed in the past.11,31,32 Lin et al reported that
approximately one-third of KD patients in the ICU group
developed moderate tricuspid regurgitation on initial
echocardiography.33 They proposed that the cause of
valvular regurgitation was possibly attributable to
myocarditis or papillary muscle dysfunction. Shinohala
et al also reported one KD patient with severe tricuspid
regurgitation and left ventricle dysfunction after an
endomyocardial biopsy, and suggested the involvement of
myocarditis in the development of tricuspid regurgita-
tion.34 Although our study dose not show the evidence of
valvular regurgitation nor myocarditis from KDSS patients
in the acute phase, we still need to keep in mind that KDSS
resulted in a severe inflammatory reaction and eventransient valvular regurgitation, myocarditis, and heart
failure.
Kanegaye et al revealed that KDSS patients had lower
age-adjusted hemoglobin z scores,11 and Dominguez et al
found that KDSS patients had lower serum albumin levels.12
Both studies showed female sex predominance and had
greater proportions of bands, lower platelet counts, and
higher CRP concentrations. There were no differences in
age between shock and hemodynamic normal groups. By
contrast, we found that the KDSS patients had risk factors
such as bandemia, neutrophilia, thrombocytopenia, and
elevated CRP, but there were no significant differences in
age and sex between the KDSS and KD groups. Younger age
does not imply a higher risk of developing KDSS. Female sex
is strongly associated with shock,11,12 but KD is more com-
mon in males. The reason for this finding is unclear and
merits additional investigation.
In our study, we found that three KDSS patients had
prolonged cardiac complications: one had mitral regurgi-
tation, another had right coronary artery, and the other had
dilated right ventricle, mitral regurgitation, and tricuspid
regurgitation. A national database study showed that cor-
onary complications occurred in 5.37% of KD cases. An
acute myocardial infarction occurred in 0.08%, of whom
one-third were aged 10e15 years.35 Therefore, we need to
follow-up these KDSS patients as long as possible because
they have a higher prevalence of developing cardiac com-
plications and may have sequelae of coronary artery dis-
ease accompanied with a higher risk of mortality.
Compared with KD patients, our KDSS patients had a
higher failure rate after first IVIG treatment. IVIG has a
generalized anti-inflammatory effect with reduction of
fever and acute markers of inflammation, included modu-
lating cytokine levels and production, downregulating
antibody synthesis.36 KDSS patients may be misdiagnosed
initially, so delay in treatment with IVIG may occur. More
prominent inflammatory markers are found in these pa-
tients. We suppose that delayed treatment and more se-
vere inflammation may make them more likely to be IVIG
resistant.
The limitations in our study are that its retrospective
nature might misclassify patients with KDSS, and our case
number is too small to analyze the full spectra of this
phenomenon and to identify all the independent risk fac-
tors. Our control group had a high proportion of incomplete
KD.37,38 This is a caseecontrol study, and the control pa-
tients were selected by season matching to each case pa-
tient by date of admission 4 weeks. We supposed that KD
has seasonal variation, so we randomized selected control
patients during the same period. The KDSS patients had
atypical clinical presentation especially at admission, but
they might develop other KD signs later. Patients in the
control group also had a high proportion of atypical fea-
tures in this study, which may reveal a trend of incomplete
KD disease at the same period, but they were diagnosed
and received treatment earlier. Because KDSS patients
were not diagnosed and treated early enough, their course
persisted and became more severe. Five of our control
incomplete KD patients had BCG erythema. This presenta-
tion has been regarded as an important sign for diagnosis of
KD,39,40 but it is not regarded as a KD diagnostic criterion
for calculation in this study.
Kawasaki disease shock syndrome 49In conclusion, patients with KDSS may have an uneven
clinical course and may be misdiagnosed when they are first
examined. They may have more prominent inflammatory
markers and result in shock and hypotension, which re-
quires critical care support at an early stage. They have a
greater risk of coronary artery abnormalities, which may
become coronary artery disease. These patients frequently
fail to fulfill the full spectra of KD in the early phase, so
delay in IVIG treatment may occur. They are also likely to
be IVIG resistant because of more severe inflammation.
Early recognition of KDSS and provision of adequate therapy
are most important.
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